Gianluca Fuggetta - 12 Dec 2022 Form 3 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Principal Accounting Officer
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
12 Dec 2022
Net transactions value
$0
Form type
3
Filing time
21 Dec 2022, 15:14:59 UTC
Next filing
27 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GANX Employee Stock Option (right to buy) 12 Dec 2022 Common Stock 10,000 $3.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on July 1, 2023 and the remainder shall vest in 36 substantially equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney